Tenax Therapeutics Inc (TENX) - Total Liabilities
Based on the latest financial reports, Tenax Therapeutics Inc (TENX) has total liabilities worth $7.16 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tenax Therapeutics Inc - Total Liabilities Trend (1995–2025)
This chart illustrates how Tenax Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Tenax Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Tenax Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Tenax Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sunplus Innovation Technology Inc.
TWO:5236
|
Taiwan | NT$460.66 Million |
|
High Liner Foods Incorporated
TO:HLF
|
Canada | CA$527.99 Million |
|
Shenzhen Capol International & Associates Co Ltd
SHE:002949
|
China | CN¥1.34 Billion |
|
Parag Milk Foods Limited
NSE:PARAGMILK
|
India | Rs10.22 Billion |
|
Rana Gruber AS
OL:RANA
|
Norway | Nkr783.91 Million |
|
Metropolis Healthcare Limited
NSE:METROPOLIS
|
India | Rs5.49 Billion |
|
Arvind SmartSpaces Limited
NSE:ARVSMART
|
India | Rs19.07 Billion |
|
Guangdong Yantang Dairy Co Ltd
SHE:002732
|
China | CN¥536.15 Million |
Liability Composition Analysis (1995–2025)
This chart breaks down Tenax Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Tenax Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tenax Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tenax Therapeutics Inc (1995–2025)
The table below shows the annual total liabilities of Tenax Therapeutics Inc from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.16 Million | +52.48% |
| 2024-12-31 | $4.69 Million | +30.85% |
| 2023-12-31 | $3.59 Million | +87.58% |
| 2022-12-31 | $1.91 Million | +9.41% |
| 2021-12-31 | $1.75 Million | -22.09% |
| 2020-12-31 | $2.24 Million | -13.49% |
| 2019-12-31 | $2.59 Million | +65.60% |
| 2018-12-31 | $1.57 Million | +55.19% |
| 2017-12-31 | $1.01 Million | -83.73% |
| 2016-12-31 | $6.20 Million | -50.66% |
| 2015-12-31 | $12.56 Million | +19.15% |
| 2014-12-31 | $10.54 Million | 0.00% |
| 2013-12-31 | $10.54 Million | +190.04% |
| 2012-12-31 | $3.64 Million | -46.24% |
| 2011-12-31 | $6.76 Million | +382.26% |
| 2010-12-31 | $1.40 Million | +16.95% |
| 2009-12-31 | $1.20 Million | -33.10% |
| 2008-12-31 | $1.79 Million | -27.15% |
| 2007-12-31 | $2.46 Million | +479.35% |
| 2006-12-31 | $424.57K | +35.24% |
| 2005-12-31 | $313.94K | -13.16% |
| 2004-12-31 | $361.51K | +8.32% |
| 2003-12-31 | $333.75K | +309.28% |
| 2002-12-31 | $81.55K | -79.52% |
| 2001-12-31 | $398.09K | +15.24% |
| 2000-12-31 | $345.44K | -42.43% |
| 1999-12-31 | $600.00K | -5.42% |
| 1998-12-31 | $634.36K | +5.61% |
| 1997-12-31 | $600.67K | -39.42% |
| 1996-12-31 | $991.54K | 0.00% |
| 1995-12-31 | $991.54K | -- |
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imat… Read more